Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Briquilimab (JSP191) conditioning for stem cell transplant in Fanconi anemia
NCT04784052Phase 2Recruiting
- Start
- Dec 2021
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of briquilimab in Fanconi anemia (FA). Started Dec 2021; status: recruiting.
02
Drugs
briquilimab
03
Conditions
Fanconi anemia (FA)
Beyond the preview
Go deeper on NCT04784052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04784052.